Bird
HHS Awards Moderna $590 Million to Expedite Bird Flu Vaccine Development
Moderna, HHS, Bird Flu Vaccine, Avian Influenza, mRNA Vaccine, Pandemic Preparedness
National Resilience Lays Off 120 Employees at Former Bluebird Bio Gene Therapy Facility in Durham, North Carolina
National Resilience, Layoffs, Gene Therapy, Bluebird Bio, Durham/ North Carolina, Biotech Industry, CDMO (Contract Development and Manufacturing Organization)
Aviceda Secures $200M Series C Funding to Advance Ocular Drug AVD-104 into Late-Stage Trials
Aviceda Therapeutics, AVD-104, Geographic Atrophy, Age-Related Macular Degeneration, Diabetic Macular Edema, Series C Funding, Late-Stage Clinical Trials
Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025
JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology
Controversial Stanford Professor Jay Bhattacharya Nominated by Trump to Lead NIH Amid Criticism Over Pandemic Views
Jay Bhattacharya, NIH Director Nomination, COVID-19 Pandemic Response Critic, Stanford University Professor, Trump Administration, Public Health Research, Controversial Appointment
PTC Therapeutics Discontinues Utreloxastat Program Following Phase 2 ALS Trial Failure
PTC Therapeutics, Utreloxastat, ALS, Phase 2 Trial, CardinALS Study, Amyotrophic Lateral Sclerosis
Trump’s NIH Leadership Plans: From Jay Bhattacharya to a More Traditional Pick?
Trump, NIH, Jay Bhattacharya, Warp Speed, Leadership, Biomedical Research
Trump Nominates Renowned Surgeon Martin Makary as FDA Commissioner
Martin Makary, FDA Commissioner, Donald Trump, Johns Hopkins, Surgeon, Nomination
Trump Nominates Surgeon Martin Makary for FDA Commissioner Amid Criticism of COVID Mandates
Trump, FDA, Martin Makary, COVID mandates, surgeon, nomination
Bluebird Bio Confronts Financial Crunch Amidst Breakeven Projections
Bluebird Bio, cash gap, breakeven point, financial stability, gene therapy, cash flow